Similar Search Results

Collusion in the US generic drug industry

Clark, Robert; Fabiilli, Christopher Anthony; Lasio, Laura - 2021

We study cartels that operated in the US generic drug industry, leveraging quarterly Medicaid data from 2011-2018 and a difference-in-differences approach comparing the evolution of prices of allegedly collusive drugs with a group of competitive control drugs. Our analysis highlights (i) the...

Persistent link: https://www.econbiz.de/10012670921

Pharmacy Benefit Managers and Generic Pharmaceuticals Pricing Conspiracy : Unveiling Lock-In Mechanisms, Structural Shortcomings and Antitrust Evidence

Yoo, Kwanghyuk - 2018

Titanic-scale multistate generic pricing antitrust litigation has been underway since December 2016, involving increasingly a myriad of generic drug manufacturers and drugs. Forty-seven states allege a pricing conspiracy wherein twenty defendants participated in a multitude of specific...

Persistent link: https://www.econbiz.de/10014111724

Pharmacy Benefit Managers and Generic Pharmaceuticals Pricing Conspiracy : Unveiling Lock-In Mechanisms, Structural Shortcomings and Antitrust Evidence

Yoo, Kwanghyuk David - 2019

Titanic-scale multistate generic pricing antitrust litigation has been underway since December 2016, increasingly involving a myriad of generic drug manufacturers and drugs. Forty-seven states allege a pricing conspiracy wherein twenty defendants participated in a multitude of specific...

Persistent link: https://www.econbiz.de/10012871612

Product patents and access to innovative medicines in a post-trips-era

Watal, Jayashree; Dai, Rong - 2019 - Manuscript date: 28 March 2019

finds that introduction of product patent for pharmaceuticals in the patent law has a positive effect on launch likelihood … pharmaceuticals are launched sooner than non-innovative ones, irrespective of the patent regime in the local market. Using a panel …This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era …

Persistent link: https://www.econbiz.de/10011992779

Non-Tariff Barriers and Bargaining in Generic and Off-Patent Pharmaceuticals

Ganapati, Sharat; McKibbin, Rebecca - 2019

Pharmaceutical prices are widely dispersed across countries with comparable quality standards. We study two elements of this dispersion; non-tariff barriers and buyer bargaining power. Under monopoly, generic drug prices are 3-4 times higher in the United States. With 6 or more competitors,...

Persistent link: https://www.econbiz.de/10014108967

Canada's Patented Medicines (Notice of Compliance) Regulations : Removing Inefficiencies to Encourage Generic Competition

Porter, Suzanne - 2013

action that evaluates patent validity. An economic incentive to challenge weak patents should also be introduced in Canada …

Persistent link: https://www.econbiz.de/10013074086

Hospitals and the generic versus brand-name prescription decision in the outpatient sector

Pruckner, Gerald J.; Schober, Thomas - 2016

Healthcare payers try to reduce costs by promoting the use of cheaper generic drugs. We show that there are strong interrelations in drug prescriptions between the inpatient and the outpatient sector using a large administrative dataset from Austria. Patients with prior hospital visits have a...

Persistent link: https://www.econbiz.de/10011519140

Hospitals and the generic versus brand-name prescription decision in the outpatient sector

Pruckner, Gerald J.; Schober, Thomas - 2016

Healthcare payers try to reduce costs by promoting the use of cheaper generic drugs. We show strong interrelations in drug prescriptions between the inpatient and outpatient sectors by using a large administrative dataset from Austria. Patients with prior hospital visits have a significantly...

Persistent link: https://www.econbiz.de/10011570769

Chapter Twelve. Markets for Pharmaceutical Products

Scott Morton, Fiona; Kyle, Margaret - In: Handbook of health economics : volume 2, (pp. 763-823). 2011

This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is … the application of biotechnology to drug development as well as firms that specialize in low-cost production of off-patent …

Persistent link: https://www.econbiz.de/10014025576

Does reference pricing drive out generic competition in pharmaceutical markets? : evidence from a policy reform

Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022

Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...

Persistent link: https://www.econbiz.de/10013285854